SOX2 and central nervous system cancer: In contrast, the expression of Ki67 and STAT3 target genes (CCND1 and SOX2) were significantly reduced in the MH2-treated xenografts (Supplementary Figure 16d–f), indicating a therapeutic effect of TAT-MH2-NLS protein for glioma.